600535 Share Price Performance
CN¥15.80
-1.18 (-6.95%)
Price CN¥15.80
Share PriceCN¥15.80
An Intrinsic Calculation For Tasly Pharmaceutical Group Co., Ltd (SHSE:600535) Suggests It's 23% Undervalued
Mar 25
Tasly Pharmaceutical Group Co., Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
600535 Community Narratives
There are no narratives available yet.
Tasly Pharmaceutical Group Co., Ltd Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Oct 25, 2025
- Earnings per share (EPS)
- 0.71
- Gross Margin
- 66.88%
- Net Profit Margin
- 12.69%
- Debt/Equity Ratio
- 12.7%
Tasly Pharmaceutical Group Co., Ltd Competitors
Snowflake Analysis
About 600535
- Founded
- 1994
- Employees
- 10958
- CEO
- WebsiteView website
Tasly Pharmaceutical Group Co., Ltd engages in the pharmaceutical business in China and internationally. The company provides prescription drugs covering various therapeutic areas, including cardiovascular and cerebrovascular, hepato-biliary-pancreatic, respiratory system, diabetes, tumor immunity, gastrointestinal disease, gynecological, rheumatism, soothe the nerves, pruritus, and andrological areas, as well as over-the-counter drugs. Tasly Pharmaceutical Group Co., Ltd was founded in 1994 and is headquartered in Tianjin, China.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Chinese Market Performance
- 7 Days: 1.8%
- 3 Months: 18.3%
- 1 Year: 24.1%
- Year to Date: 26.2%
In the last week, the market is up 1.8% led by Industrials sector. In the last year, the market has climbed 24%. As for the next few years, earnings are expected to grow by 27% per annum. Market details ›